Medtronic Change in Accounts Payable 2010-2025 | MDT
Medtronic annual/quarterly change in accounts payable history and growth rate from 2010 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
- Medtronic change in accounts payable for the quarter ending January 31, 2025 was $0M, a 0% increase year-over-year.
- Medtronic change in accounts payable for the twelve months ending January 31, 2025 was $0M, a 0% increase year-over-year.
- Medtronic annual change in accounts payable for 2024 was $0B, a 0% decline from 2023.
- Medtronic annual change in accounts payable for 2023 was $0B, a 0% decline from 2022.
- Medtronic annual change in accounts payable for 2022 was $0B, a 0% decline from 2021.
| Medtronic Annual Change in Accounts Payable (Millions of US $) |
|
|---|---|
| 2024 | $N/A |
| 2023 | $N/A |
| 2022 | $N/A |
| 2021 | $N/A |
| 2020 | $N/A |
| 2019 | $N/A |
| 2018 | $N/A |
| 2017 | $N/A |
| 2016 | $N/A |
| 2015 | $N/A |
| 2014 | $N/A |
| 2013 | $N/A |
| 2012 | $N/A |
| 2011 | $N/A |
| 2010 | $N/A |
| 2009 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $107.169B | $32.364B |
| Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions. | |||